FDA panel rejects ALS treatment from Brainstorm Cell Therapeutics

A U.S. Food and Drug Administration advisory committee voted against a treatment from BrainStorm Cell Therapeutics
BCLI,
-8.35%
for amyotrophic lateral sclerosis, or ALS.

The FDA panel’s vote was 17-1, with one adviser abstaining.

Patients last year petitioned the FDA to consider the treatment, called NurOwn, in a public hearing. The agency said the company submitted “scientifically incomplete” and “grossly deficient” data.